Included in the chemokines family, elevated CX3CL1 (fractalkine) plasma levels have been found in mild cognitive impairment (MCI) and mild AD patients [12], as well as an increase of CX3CL1 gene expression in the brains of AD patients in respect to control subjects, mainly in the early stage [13]. The gene discussed is CX3CL1; the disease is Alzheimer disease.